Submission on Proposal to fund Risdiplam (Evrysdi) for Spinal Muscular Atrophy
Rare Disorders NZ has made a submission to Pharmac on the Proposal to fund Risdiplam (Evrysdi) for Spinal Muscular Atrophy.
Rare Disorders NZ supports the funding proposal for Risdiplam which we understand would have the same access criteria as nusinersen (Spinraza) for the treatment of symptomatic type 1, 2 and 3a SMA for people who start treatment when they are 18 years or younger.
Rare Disorders NZ supports two funded options for the treatment of symptomatic SMA in New Zealand, especially as Risdiplam would provide an oral treatment option alongside nusinersen.
Read our full submission here.